Abstract:Background: Most people are infected with COVID-19 during pandemics at the end of 2022. Older patients were more vulnerable. However, the incidence of secondary bacterial, fungal or viral pulmonary infection and co-infection is not well described in elderly hospitalized COVID-19 patients. Methods: We retrospectively reviewed the medical records of all elderly (≥65 years) hospitalized patients with laboratory-confirmed COVID-19 from December 1, 2022 to January 31, 2023. Demographics, underlying diseases, treatments, and laboratory data were collected. Univariate and multivariate logistic regression models were used to explore the risk factors associated with secondary bacterial, fungal or viral pulmonary infection and co-infection. Results: A total of 322 older patients with COVID-19 were enrolled. The incidence of secondary bacterial, fungal or viral pulmonary infection and co-infection was 27.3% (88/322) and 7.5% (24/322), respectively. The overall in-hospital mortality of all patients was 32.9% (106/322), and the in-hospital mortality among patients who acquired with secondary pulmonary infection and co-infection was 57.0% (57/100). A total of 23.9% (77/322) of patients were admitted to ICU within 48 h of hospitalization. The incidence of secondary pulmonary infection and co-infection among patients admitted to the ICU was 50.6% (39/77) and 13.0% (10/77), respectively. The overall in-hospital mortality of ICU patients was 48.1% (37/77), and the in-hospital mortality of ICU patients acquired with secondary pulmonary infection and co-infection was 61.4% (27/44). A total of 83.5% (269/322) of the included patients received empirical antibiotic therapy before positive Clinical Microbiology results. Influenza A virus (the vast majority were the H3N2 subtype) was the most common community acquired pathogen for co-infection. While A. baumannii, K. pneumoniae, and P. aeruginosa were the common hospital acquired pathogens for co-infection and secondary pulmonary infection. The incidence of Carbapenem-resistant Gram-negative bacilli (CR-GNB) infections was high, and the mortality reached 76.9%. Predictors of secondary pulmonary infection and co-infection were ICU admission within 48 h of hospitalization, cerebrovascular diseases, critical COVID-19, and PCT > 0.5 ng/mL. Conclusion: The prognosis for elderly hospitalized COVID-19 patients with secondary pulmonary infection or co-infection is poor. The inflammatory biomarker PCT > 0.5 ng/mL played an important role in the early prediction of secondary pulmonary infection and co-infection in COVID-19 patients.

Prevalence, risk factors and outcomes of secondary infections among hospitalised patients with COVID-19 or post-COVID-19 conditions in Victoria, 2020-2023

Secondary bacterial infections in critical ill patients of COVID-19

Secondary infection in COVID-19 critically ill patients: a retrospective single-center evaluation

Risks and Features of Secondary Infections in Severe and Critical Ill COVID-19 Patients

Incidence of secondary bacterial infections and risk factors for in-hospital mortality among coronavirus disease 2019 subjects admitted to secondary care hospital: A single-center cross-sectional retrospective study

Secondary Bacterial Infections in Patients With Viral Pneumonia

Bacterial and fungal secondary infections occurring in COVID-19 patients followed in intensive care: a retrospective study

Secondary Infection in Severe and Critical COVID-19 Patients in China: a Multicenter Retrospective Study.

Clinical and etiological analysis of co-infections and secondary infections in COVID-19 patients: An observational study

Secondary infections in critically ill patients with viral pneumonia due to COVID-19 and influenza: a historical cohort study

Secondary pulmonary infection and co-infection in elderly COVID-19 patients during the pandemics in a tertiary general hospital in Beijing, China

Diagnostic significance of secondary bacteremia in patients with COVID-19

Secondary Bacterial Infections in Critical Ill Patients with Coronavirus Disease 2019.

Outcomes for people admitted to Australian and New Zealand intensive care units with primary, exacerbating, or incidental SARS‐CoV‐2 infections, 2022–23: a retrospective analysis of ANZICS data

Bacterial co-infection and secondary infection in patients with COVID-19: a living rapid review and meta-analysis

Bacterial co-infections and secondary infections and their antimicrobial resistance in Covid-19 patients during the second pandemic wave

Bacterial infections in critically ill patients with SARS-2-COVID-19 infection: results of a prospective observational multicenter study

Community-acquired and hospital-acquired respiratory tract infection and bloodstream infection in patients hospitalized with COVID-19 pneumonia

Etiology and antimicrobial resistance of secondary bacterial infections in patients hospitalized with COVID-19 in Wuhan, China: a retrospective analysis

Secondary Bacterial Infection and Clinical Characteristics in Patients With COVID-19 Admitted to Two Intensive Care Units of an Academic Hospital in Iran During the First Wave of the Pandemic

Co-infection in critically ill patients with COVID-19: an observational cohort study from England